Dermatological Sciences, University of Manchester, Manchester Academic Health Science Centre, Salford Royal NHS Foundation Trust, Manchester, UK.
Dermatol Ther (Heidelb). 2012 Dec;2(1):8. doi: 10.1007/s13555-012-0008-4. Epub 2012 Jun 7.
Actinic keratoses (AK) are the most common premalignant pathology seen in dermatological practice and represent a burgeoning burden upon health services. Increasingly recognized is the damage to surrounding, perilesional skin, forming the premise for field-directed therapy. Ingenol mebutate gel is a novel agent for field-directed treatment of AK, requiring only 2 or 3 days of application. Following an overview of existing treatment modalities, the authors review recent trials and safety data pertaining to the use of ingenol mebutate gel and discuss its role in the treatment of AK.
光化性角化病（AK）是皮肤科最常见的癌前病变，对卫生服务系统造成了越来越大的负担。人们越来越认识到周围病变皮肤的损伤，这为定向治疗提供了前提。 Ingenol 咪喹莫特凝胶是一种用于 AK 定向治疗的新型药物，仅需应用 2 至 3 天。在概述了现有的治疗方法后，作者回顾了 Ingenol 咪喹莫特凝胶的近期临床试验和安全性数据，并讨论了其在 AK 治疗中的作用。
